Evidence map›Paper›PMID 37741989›Full record

ArticleJournal of translational medicine2023

Urinary peptides provide information about the risk of mortality across a spectrum of diseases and scenarios.

Felix Keller, Joachim Beige, Justyna Siwy, Alexandre Mebazaa, Dewei An, Harald Mischak, Joost P Schanstra, Marika Mokou, Paul Perco, Jan A Staessen and 2 more

Open access · goldAbstract read
In one paragraph

Article in Journal of translational medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 8 institutions in 5 countries.

Felix KellerDepartment of Internal Medicine IV (Nephrology and Hypertension), Medical University Innsbruck, 6020, Innsbruck, Austria.
Joachim BeigeMartin-Luther-University Halle-Wittenberg, 06108, Halle (Saale), Germany.
Justyna SiwyMosaiques Diagnostics GmbH, 30659, Hannover, Germany.
Alexandre MebazaaDepartment of Anaesthesiology and Critical Care, Hôpital Lariboisière, AP-HP, 75010, Paris, France.
Dewei AnNon-Profit Research Association Alliance for the Promotion of Preventive Medicine, 2800, Mechelen, Belgium.
Harald MischakMosaiques Diagnostics GmbH, 30659, Hannover, Germany.
Joost P SchanstraInstitute of Cardiovascular and Metabolic Disease, U1297, Institut National de la Santé et de la Recherche Médicale, 31432, Toulouse, France.
Marika MokouMosaiques Diagnostics GmbH, 30659, Hannover, Germany.
Paul PercoDepartment of Internal Medicine IV (Nephrology and Hypertension), Medical University Innsbruck, 6020, Innsbruck, Austria.
Jan A StaessenNon-Profit Research Association Alliance for the Promotion of Preventive Medicine, 2800, Mechelen, Belgium.
Antonia VlahouCenter of Systems Biology, Biomedical Research Foundation of the Academy of Athens, 11527, Athens, Greece.
Agnieszka LatosinskaMosaiques Diagnostics GmbH, 30659, Hannover, Germany. latosinska@mosaiques-diagnostics.com.ORCID http://orcid.org/0000-0001-8917-2412
Innsbruck Medical University · ATMosaiques Diagnostics and Therapeutics (Germany) · DEUniversité Toulouse III - Paul Sabatier · FRAcademy of Athens · GRAssistance Publique – Hôpitaux de Paris · FRKlinikum St. Georg · DEKU Leuven · BENational and Kapodistrian University of Athens · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere is evidence of pre-established vulnerability in individuals that increases the risk of their progression to severe disease or death, although the mechanisms causing this are still not fully understood. Previous research has demonstrated that a urinary peptide classifier (COV50) predicts disease progression and death from SARS-CoV-2 at an early stage, indicating that the outcome prediction may be partly due to vulnerabilities that are already present. The aim of this study is to examine the ability of COV50 to predict future non-COVID-19-related mortality, and evaluate whether the pre-established vulnerability can be generic and explained on a molecular level by urinary peptides.

methodsUrinary proteomic data from 9193 patients (1719 patients sampled at intensive care unit (ICU) admission and 7474 patients with other diseases (non-ICU)) were extracted from the Human Urinary Proteome Database. The previously developed COV50 classifier, a urinary proteomics biomarker panel consisting of 50 peptides, was applied to all datasets. The association of COV50 scoring with mortality was evaluated.

resultsIn the ICU group, an increase in the COV50 score of one unit resulted in a 20% higher relative risk of death [adjusted HR 1.2 (95% CI 1.17-1.24)]. The same increase in COV50 in non-ICU patients resulted in a higher relative risk of 61% [adjusted HR 1.61 (95% CI 1.47-1.76)], consistent with adjusted meta-analytic HR estimate of 1.55 [95% CI 1.39-1.73]. The most notable and significant changes associated with future fatal events were reductions of specific collagen fragments, most of collagen alpha I (I).

conclusionThe COV50 classifier is predictive of death in the absence of SARS-CoV-2 infection, suggesting that it detects pre-existing vulnerability. This prediction is mainly based on collagen fragments, possibly reflecting disturbances in the integrity of the extracellular matrix. These data may serve as a basis for proteomics-guided intervention aiming towards manipulating/ improving collagen turnover, thereby reducing the risk of death.

Indexed as

COVID-19Collagen Type IHumansPeptidesProteomicsSARS-CoV-2Collagen Type IPeptidesDeathMass spectrometryPeptidomicsPersonalised medicineUrinary biomarkers

Identifiers

PMID37741989
PMCPMC10518109
OpenAlexW4386993685

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.